RxDoctor Payments Data

Michael Kometa, MD

Adolescent Medicine · Petersburg, VANPI 1700042231

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $538 of the $801 with a category attached, or 67.1%. 8 manufacturers reported payments, led by Biomerieux Inc at 32.9% of the total. Reporting peaked in 2022 at $492 and has fallen 97.1% since, to $14 in 2025.

$801in general payments, 2019–2025

Across 22 payments — averaging $36.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomerieux Inc$264
  • Johnson & Johnson$252
  • Pfizer$101
  • AstraZeneca$94
  • Boehringer Ingelheim$35
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23
  • plus $34 from 2 others

What the payments were for

  • Consulting fees$26433%
  • Food & beverage$53867%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$801 in reported general payments places this provider in the 60th percentile of 49 adolescent medicine providers in Virginia.

See all adolescent medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$110,617
Medicare patients
493
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$12,521
Midodrine Hcl13$647
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$225
Doxycycline Hyclate32$203
Potassium Chloride13$86
Pantoprazole Sodium16$81
Pravastatin Sodium13$72
Prednisone37$67
Metoprolol Succinate24$59
Atorvastatin Calcium16$54
Furosemide22$49
Levofloxacin17$47
Amlodipine Besylate21$43
Oxycodone Hcl11$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$101$12,52121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 49 adolescent medicine providers in Virginia.

Other adolescent medicine in Petersburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →